238 related articles for article (PubMed ID: 29273385)
21. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
[TBL] [Abstract][Full Text] [Related]
22. Alterations of membrane lipids and in gene expression of ganglioside metabolism in different brain structures in a mouse model of mucopolysaccharidosis type I (MPS I).
Kreutz F; dos Santos Petry F; Camassola M; Schein V; Guma FC; Nardi NB; Trindade VM
Gene; 2013 Sep; 527(1):109-14. PubMed ID: 23774686
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of biomarkers for Sanfilippo syndrome.
Saville JT; Flanigan KM; Truxal KV; McBride KL; Fuller M
Mol Genet Metab; 2019; 128(1-2):68-74. PubMed ID: 31104888
[TBL] [Abstract][Full Text] [Related]
24. Comparison of dermatan sulfate and heparan sulfate concentrations in serum, cerebrospinal fluid and urine in patients with mucopolysaccharidosis type I receiving intravenous and intrathecal enzyme replacement therapy.
Zhang H; Dickson PI; Stiles AR; Chen AH; Le SQ; McCaw P; Beasley J; Millington DS; Young SP
Clin Chim Acta; 2020 Sep; 508():179-184. PubMed ID: 32442432
[TBL] [Abstract][Full Text] [Related]
25. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
[TBL] [Abstract][Full Text] [Related]
26. Quantification of Glycosaminoglycans in Urine by Isotope-Dilution Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry.
Zhang H; Young SP; Millington DS
Curr Protoc; 2023 Mar; 3(3):e701. PubMed ID: 36929617
[TBL] [Abstract][Full Text] [Related]
27. Mucopolysaccharidosis type I.
Wraith JE; Jones S
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
[TBL] [Abstract][Full Text] [Related]
28. Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases.
Langford-Smith KJ; Mercer J; Petty J; Tylee K; Church H; Roberts J; Moss G; Jones S; Wynn R; Wraith JE; Bigger BW
J Inherit Metab Dis; 2011 Apr; 34(2):499-508. PubMed ID: 21170681
[TBL] [Abstract][Full Text] [Related]
29. A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses.
Chuang CK; Lin HY; Wang TJ; Tsai CC; Liu HL; Lin SP
Orphanet J Rare Dis; 2014 Sep; 9():135. PubMed ID: 25178307
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of non-reducing end pathologic glycosaminoglycan detection method for monitoring therapeutic response to enzyme replacement therapy in human mucopolysaccharidosis I.
Vera MU; Le SQ; Victoroff A; Passage MB; Brown JR; Crawford BE; Polgreen LE; Chen AH; Dickson PI
Mol Genet Metab; 2020 Feb; 129(2):91-97. PubMed ID: 31630958
[TBL] [Abstract][Full Text] [Related]
31. Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.
Entchev E; Jantzen I; Masson P; Bocart S; Bournique B; Luccarini JM; Bouchot A; Lacombe O; Junien JL; Broqua P; Tallandier M
PLoS One; 2020; 15(5):e0233032. PubMed ID: 32413051
[TBL] [Abstract][Full Text] [Related]
32. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.
Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440
[TBL] [Abstract][Full Text] [Related]
33. Differences in MPS I and MPS II Disease Manifestations.
Hampe CS; Yund BD; Orchard PJ; Lund TC; Wesley J; McIvor RS
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360653
[TBL] [Abstract][Full Text] [Related]
34. Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase.
Chen A; Vogler C; McEntee M; Hanson S; Ellinwood NM; Jens J; Snella E; Passage M; Le S; Guerra C; Dickson P
APMIS; 2011 Aug; 119(8):513-21. PubMed ID: 21749451
[TBL] [Abstract][Full Text] [Related]
35. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI.
Auray-Blais C; Bhérer P; Gagnon R; Young SP; Zhang HH; An Y; Clarke JT; Millington DS
Mol Genet Metab; 2011 Jan; 102(1):49-56. PubMed ID: 20934363
[TBL] [Abstract][Full Text] [Related]
36. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts.
Friso A; Tomanin R; Alba S; Gasparotto N; Puicher EP; Fusco M; Hortelano G; Muenzer J; Marin O; Zacchello F; Scarpa M
J Gene Med; 2005 Nov; 7(11):1482-91. PubMed ID: 15966019
[TBL] [Abstract][Full Text] [Related]
37. Mucopolysaccharidosis type V. (Scheie syndrome). A postmortem study by multidisciplinary techniques with emphasis on the brain.
Dekaban AS; Constantopoulos G; Herman MM; Steusing JK
Arch Pathol Lab Med; 1976 May; 100(5):237-45. PubMed ID: 817693
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of a Combination Therapy with Laronidase and Genistein in Treating Mucopolysaccharidosis Type I in a Mouse Model.
Malinowska M; Nowicka W; Kloska A; Węgrzyn G; Jakóbkiewicz-Banecka J
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397051
[TBL] [Abstract][Full Text] [Related]
39. High-Throughput Liquid Chromatography-Tandem Mass Spectrometry Quantification of Glycosaminoglycans as Biomarkers of Mucopolysaccharidosis II.
Wang J; Bhalla A; Ullman JC; Fang M; Ravi R; Arguello A; Thomsen E; Tsogtbaatar B; Guo JL; Skuja LL; Dugas JC; Davis SS; Poda SB; Gunasekaran K; Costanzo S; Sweeney ZK; Henry AG; Harris JM; Henne KR; Astarita G
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751752
[TBL] [Abstract][Full Text] [Related]
40. Progressive heart disease in mucopolysaccharidosis type I mice may be mediated by increased cathepsin B activity.
Baldo G; Tavares AM; Gonzalez E; Poletto E; Mayer FQ; Matte UD; Giugliani R
Cardiovasc Pathol; 2017; 27():45-50. PubMed ID: 28104572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
